Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.60
+0.45 (8.74%)
At close: Mar 27, 2026

Lepu Biopharma Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-411.38-22.1-689.05-1,011
Depreciation & Amortization
100.03102.4395.4595.25
Other Amortization
0.150.15--
Loss (Gain) From Sale of Assets
0.01--0.61-
Loss (Gain) From Sale of Investments
--220.26--5.37
Loss (Gain) on Equity Investments
16.4427.3432.2317.7
Stock-Based Compensation
4.418.5730.42113.51
Provision & Write-off of Bad Debts
0.20.21--
Other Operating Activities
5.73-168.8721.9758.61
Change in Accounts Receivable
-8.22-38.01--20.37
Change in Inventory
6.63-5.350.12-4.62
Change in Accounts Payable
28.5241.482.55134.56
Change in Unearned Revenue
7.11---
Change in Other Net Operating Assets
53.9913.5825.99-
Operating Cash Flow
-196.39-250.84-480.93-621.74
Capital Expenditures
-32.92-28-110.45-213.39
Cash Acquisitions
---10-100
Sale (Purchase) of Intangibles
-28.83-13.2-5-6.12
Investment in Securities
-125.1450.79315.61
Investing Cash Flow
-61.7583.94-74.66-3.89
Long-Term Debt Issued
584.41403.55437.46146.11
Total Debt Issued
584.41403.55437.46146.11
Long-Term Debt Repaid
-488.63-383.99-88.76-15.82
Total Debt Repaid
-488.63-383.99-88.76-15.82
Net Debt Issued (Repaid)
95.7819.56348.7130.3
Issuance of Common Stock
213.38-739.23261.12
Other Financing Activities
-77.07-96.26-55.96-11.11
Financing Cash Flow
232.08-76.71,032380.31
Foreign Exchange Rate Adjustments
1.330.2137.86-2.38
Net Cash Flow
-24.73-243.38514.23-247.7
Free Cash Flow
-229.31-278.84-591.38-835.12
Free Cash Flow Margin
-62.35%-123.73%-3797.71%-
Free Cash Flow Per Share
-0.14-0.17-0.36-0.55
Cash Interest Paid
28.2529.3821.399.29
Levered Free Cash Flow
-185.08-227.17-449.59-514.38
Unlevered Free Cash Flow
-171.55-217.99-444.93-512.69
Change in Working Capital
88.0311.728.67109.58
Source: S&P Global Market Intelligence. Standard template. Financial Sources.